4 results about "Biomodulators" patented technology

Small molecule ERα biomodulators that kill therapy-resistant ERα positive breast, ovarian, and endometrial cancer cells are disclosed. In one embodiment, the small molecule biomodulator has increased therapeutic utility because of an increased ability to kill therapy-resistant cancer cells compared to BHPI and other conventional therapies (endocrine therapies, tamoxifen, and fulvestrant / ICI). The small molecule biomodulators not only inhibit proliferation of the cancer cells but kills them, which prevents reactivation of tumors years later. Compounds of the invention, such as ErSO-TFPy, are effective for treating ERα positive cancers such as breast cancer, ovarian cancer, uterine cancer, cervical carcinoma, endometrial cancer, and the like.

A sensor array for monitoring and customizing photobiologically modulated doses is disclosed. The sensor array includes a temperature sensor for monitoring the surface temperature at the target treatment site when photons are emitted from a photobiologically modulated device onto the target treatment site.

The present invention relates to steroid derivative regulators, a method for preparing the same, and uses thereof. Specifically, the present invention relates to a compound of formula (I), a preparation method therefor, a pharmaceutical composition containing the compound, and uses thereof as a regulator the of GABA A receptor for treating depression, convulsion, Parkinson's disease, and nervous system diseases, wherein the substituents of the formula (I) are as defined in the description.

To provide steroid derivative modulators, a method for preparing the same, and uses thereof.SOLUTION: The invention relates to steroid derivative modulators, a method for preparing the same, and uses thereof. In particular, the invention relates to a compound represented by the general formula (I), a method for preparing the same, a pharmaceutical composition containing the compound, and applications thereof as a GABAA receptor modulator in treating depression, convulsion, Parkinson's disease, and nervous system diseases, where the substituents in the general formula (I) are the same as defined in the specification.SELECTED DRAWING: None